What Valneva SE does.

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best-, or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early Research & Development (“R&D”) to approvals, and currently market three proprietary travel vaccines.

Revenues from our commercial business help fuel the continued advancement of our vaccine development pipeline. Our clinical portfolio is composed of highly differentiated vaccine candidates that are designed to provide preventative solutions for diseases with high unmet need. Our pipeline includes the only Lyme disease vaccine candidate (VLA15) in advanced clinical development, which we are developing in partnership with Pfizer, as well as the world’s most clinically advanced tetravalent Shigella vaccine candidate, under development in collaboration with LimmaTech Biologics AG (“LimmaTech”), and proprietary vaccine candidates against other global public health threats.

Revenue and profit, by fiscal year.

More on VALN.

• Valneva SE summary
• Valneva SE financial statements
• Valneva SE key metrics
• Valneva SE health scores and style box
• Valneva SE earnings
• Valneva SE dividends
• Valneva SE valuation
• Valneva SE ownership and insiders
• Valneva SE peers

Figures from Valneva SE's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.